ArticleMolecular cancer therapeutics2016

Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.

Alok R Singh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.